The landscape of cognitive enhancement and neuropharmacology is undergoing a significant shift in 2026. Following the FDA recent reclassification of certain peptides from the Category 2 do not compound list to Category 1 status, two compounds have emerged at the forefront of nootropic research: Semax and Selank. Originally developed by the Institute of Molecular Genetics […]
